Table 1.
Patient characteristics at enrollment
| P-ML ID | Age, y | Sex | Cytogenetic abnormalities | HCT donor* |
HCT KIR (GvH) |
HCT KIR (HvG) |
Time to relapse after HCT | Post-HCT salvage therapies, n | T-cell donor engraftment, % | Blasts in BM at enrollment, % |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 1.5 | M | t:RUNX1 | Haplo | Match | Match | 90 d | 2 | 100 | 4 |
| 3 | 28 | F | Tetraploidy | Haplo | Mismatch | Match | 1 y | 0 | NA† | 70 |
| 4 | 7 | M | NUP98, FLT3-ITD |
Haplo | Match | Mismatch | 60 d | 1 | 90 | 45 |
| 5 | 21 | F | −5q, MECOM | MUD | Match | Match | 150 d | 4 | NA† | 10 |
| 7 | 9 | F | −5q | MSD | Match | Match | 3 y | 3 | 95 | 62 |
| 8 | 2 | F | MECOM | MSD | Match | Match | 100 d | 2 | 77 | 11 |
| 9 | 11 | F | T(11:17) | MUD/haplo | Match | Mismatch | 160 d After HCT 2 |
2 | 100 | 15 |
| 10 | 1.5 | F | KMT2A:MLLT3 | Haplo | Mismatch | Match | 60 d | 1 | 100 | 82 |
| 11 | 4 | M | NUP98 | MUD/MUD | Match | Match | 100 d after HCT 2 |
4 | 100 | 35 |
| Average (range) |
9.4 (1.5-22) |
3 M 6 F |
— | 5× Haplo 2× MUD 2× MSD |
— | — | 242 d after HCT (60-1095 d) |
2 (0-4) |
96 (77-100) |
37 (4-82) |
Included are baseline characteristics, transplant history, and prior treatment history of all patients enrolled on the clinical trial who received ML NK cell immunotherapy.
F, female; GvH, graft-versus-host; haplo, haploidentical; HCT, hematopoietic cell transplant; HvG, host-versus-graft; M, male; MSD, matched sibling donor; MUD, matched unrelated donor; NA, not available.
*
For patients who underwent 2 transplants before enrollment, donors are list as 1st HCT/2nd HCT.
†
T-cell engraftment was not available for these 2 patients. Both had bone marrow tested for donor engraftment. P-ML003 had 5% donor engraftment in bone marrow and P-ML005 had 100% donor engraftment in bone marrow.